Lumida
/LDOS
⌘K
Leidos Holdings Inc

Leidos Holdings Inc

LDOS
$106.48USD-1.67%-1.81 today

MARKET CAP

13.4B

P/E (TTM)

9.8x

FWD P/E

DAY RANGE

$106 – $111

52W RANGE

$99
$206

AI Summary

Stalk
TrimMedium

LDOS remains in a Stage 4 decline with persistent lower highs and lower lows under declining EMAs. Price is consolidating around its short-term EMA cluster following an oversold flush, but no clear rejection at resistance has emerged. Under the Stable strategy, immediate selling is premature; execution should be deferred until a rally into the declining EMA zone confirms resistance (Trim).

  • Q1 revenue up 4% YoY to $4.4B, driven by defense segment.
  • 2026 revenue guidance raised by $500M to $18–18.4B on strong backlog.
  • Negative earnings revisions point to margin pressure in fixed-price defense programs.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Leidos Holdings, Inc. (NYSE: LDOS) is a leading provider in the defense, aviation, information technology, and biomedical research sectors, specializing in offering solutions that support national security, healthcare, and infrastructure. With a strong focus on innovation and the integration of advanced technologies, Leidos aims to deliver high-impact services to its governmental and commercial clientele globally. The company's position is particularly fortified by its strategic initiatives under the "North Star 2030" growth plan, which centers around enhancing operational efficiencies and expanding its technological capabilities across vital markets such as defense and health services.

Bull says

  • Q1 revenue up 4% YoY to $4.4B, driven by defense segment.
  • 2026 revenue guidance raised by $500M to $18–18.4B on strong backlog.
  • Partnership with Modern Data Company to bolster AI-driven solutions.
  • Disciplined capital allocation with net debt of $6.3B and manageable leverage.
  • Projected operating cash flow of $1.8B in 2026 underpins investments.
  • Favorable financial profile with high earnings yield and strong liquidity.

Bear says

  • Negative earnings revisions point to margin pressure in fixed-price defense programs.
  • Healthcare segment faces competitive pricing that erodes profit margins.
  • Elevated short interest reflects bearish investor sentiment and volatility risk.
  • Leverage at 2.6x debt/EBITDA heightens exposure to rising rates.
  • Multiple analyst downgrades, including PT cut to $160 over valuation concerns.
  • Weak growth and quality factor signals may limit upside potential.

Investment themes with LDOS

Cybersecurity -2.52%

Solutions securing IT infrastructure and sensitive data

AVGO · CRWD · PANW
Defense Tech -0.44%

LMT · RTX · GD

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-08-2026bullish

Transcript signals

Bull points

  • We are off to an impressive start in 2026.
  • Non-GAAP diluted EPS grew 5% to $3.13, driven by higher adjusted EBITDA, lower share count, and a lower tax rate.
  • Intel and digital revenues increased 7% year over year, with 6% coming organically.

Bear points

  • we expect awards to pick up significantly over the course of the year.
Read full transcript analysis ›